CureVac receives 400 mln eur upfront; may get extra 1.05 bln (Il Sole 24 Ore Radiocor) - London, 03 Jul - The UK pharmaceutical group GSK said that it is acquiring full rights to develop, manufacture and commercialise globally mRNA candidate vaccines for influenza and Covid-19, including combinations, from the German firm CureVac.

CureVac will receive 400 million euros upfront and up to an additional 1.05 billion euros in development, regulatory and sales milestone payments as well as tiered royalties, said GSK.

It added that all previous financial considerations from GSK's prior collaboration with CureVac are replaced.

AAA-Web

(RADIOCOR) 03-07-24 11:18:55 (0290) 5 NNNN